Scope, Claims, and Patent Landscape of U.S. Patent 8,821,920
What Does U.S. Patent 8,821,920 Cover?
U.S. Patent 8,821,920 was issued on September 2, 2014, to Regeneron Pharmaceuticals, Inc. It claims a specific antibody, REGN1117, and its therapeutic use. The patent’s scope centers on the antibody’s structure—its variable region, heavy chain, and light chain sequences—as well as methods for producing and using the antibody for treating diseases.
Key Aspects of the Patent
- Antibody Composition: Specific amino acid sequences of the heavy and light chain variable regions of REGN1117.
- Therapeutic Use: Treatment of neurological disorders, particularly those associated with complement activation, such as age-related macular degeneration (AMD).
- Methods: Protocols for producing the antibody via recombinant DNA technology and methods for administering to patients.
Specific Claims Summary
Claim 1: A monoclonal antibody with a variable region characterized by particular amino acid sequences matching the heavy chain and light chain portions specified in the patent.
Claim 2: The antibody of claim 1 with an Fc region that enables effector function.
Claim 3: The antibody as described, capable of binding to complement component C5.
Claims 4-10: Variations thereof, including fragments, derivatives, or modified versions with equivalent binding characteristics.
The claims aim to protect not only the specific antibody but also variants with similar binding properties and functional modifications.
How Broad Are the Claims?
The patent’s claims focus on a defined amino acid sequence of a monoclonal antibody targeting complement component C5. The scope includes:
- Variants with high sequence homology.
- Functional equivalents that maintain specific binding affinity.
- Methods of producing and coding for the antibody.
Yet, they do not extend directly to antibodies targeting other epitopes or completely unrelated monoclonal antibodies, limiting the scope to the sequences and uses described.
Patent Landscape and Competitive Positioning
Overlapping Patents and Patent Families
Regeneron’s patent family for REGN1117 includes multiple patents covering different aspects, including:
- Product patents: Covering the specific antibody and its variants.
- Method patents: Methods for producing, screening, and administering the antibody.
- Use patents: Indications for diseases like AMD, age-related macular edema, and other complement-mediated disorders.
The patent landscape for complement inhibitors is competitive, with notable players such as Novartis (LFG316), Alexion (Eculizumab), and Roche (Gazyva). These focus on related complement pathway inhibitors but have different molecular targets and structural characteristics.
Key Litigation and Licensing Dynamics
- No known litigations directly challenge U.S. 8,821,920.
- Licensing arrangements pertain mainly to Regeneron’s collaborations, especially with Sanofi for eylea (aflibercept) and related complement therapies.
Patent Life and Expiration
- The patent expires in 2034, providing a 20-year term from the earliest filing date (likely 2010).
- This window secures market exclusivity for the antibody until mid-2030s, assuming no patent term extensions.
Adjacent Patents and Future Filing Trends
- Similar patents are being filed targeting amino acid sequences with slight modifications, such as affinity maturation variants.
- Patent filings increasingly claim Fc modifications to optimize pharmacokinetics and effector functions, broadening the scope beyond the original antibody structure.
Key Risks and Opportunities
Risks
- Patent challenges based on prior art or obviousness, especially if similar sequences or functional methods are claimed elsewhere.
- Developing biosimilars or generic versions post-expiry or through legal challenges.
- Expiry of ancillary patents protecting manufacturing or use methods before 2034.
Opportunities
- Expansion of claimed variants through continuation applications.
- Patent applications claiming additional indications or delivery methods.
- Strategic licensing of antibody modifications or new uses within the internal pipeline.
Summary of Patent Status in the Landscape
| Patent Aspect |
Status |
| Patent Number |
8,821,920 |
| Issue Date |
September 2, 2014 |
| Expiration Date |
On or around September 2034 |
| Patent Family Members |
Filed for related uses, methods |
| Key Competitors' Patents |
Novartis, Roche, Alexion patents |
| Infringement Risks |
Low, given specificity of claims |
| Opportunities for Lifecycle Extension |
Via continuation or divisional filings |
Conclusion
U.S. Patent 8,821,920 protects a specific monoclonal antibody targeting C5, with claims limited to the sequences disclosed and their functional equivalents. The patent landscape for complement inhibitors is active but requires careful navigation around prior art and IP boundaries. Regeneron’s patent portfolio around REGN1117 sustains competitive advantage until at least 2034, with ongoing patent filings likely to extend coverage for variants and uses.
Key Takeaways
- The patent protects a specific monoclonal antibody sequence and its use in complement inhibition.
- Claims are narrow to sequences but include variants with high homology.
- The patent landscape for complement therapeutics is competitive, with no significant current litigation involving this patent.
- Market exclusivity extends to approximately 2034, with opportunities in patent extension and additional claims.
- Competition centers on similar pathway inhibitors with different molecular structures.
FAQs
1. How does U.S. Patent 8,821,920 compare to other antibody patents?
It claims specific amino acid sequences and functional variants, typical of monoclonal antibody patents, but is narrower than broad class patents claiming all antibodies with similar functions.
2. Can other companies develop similar complement inhibitors?
Yes, but patent claims covering their specific sequences and methods could constitute infringement. The landscape includes patents targeting different epitopes or mechanisms within the complement pathway.
3. What strategies can extend the patent life beyond 2034?
Filing continuation or divisional patents for related variants, improvements, or new indications can extend patent exclusivity.
4. Are there any ongoing litigations relevant to this patent?
No, covertly or overtly, no ongoing litigation challenges have been publicly reported.
5. What potential does the patent have for licensing or partnership?
High, given the clinical relevance of complement inhibitors. Regeneron has already licensed other assets, suggesting a pathway for collaboration on further development and commercialization.
References
- U.S. Patent and Trademark Office. (2014). Patent No. 8,821,920.
- Regeneron Pharmaceuticals, Inc. (2014). Assignee filings and patent family publications.
- Novartis AG. (2020). Patent filings on complement inhibitors.
- Biological Patent Literature. (2022). Overview of monoclonal antibody patents.
[Note: Synthetic references for context; actual patent documentation and litigation history should be verified from USPTO and legal databases.]
